Aprameya Engineering Peer Comparison
NSE: APRAMEYA
₹125.50
As on 20-Nov-2026IST
Market cap
₹239 Cr
Revenue (TTM)
₹55 Cr
P/E Ratio
46.8
P/B Ratio
3.4
Div. Yield
0 %
| Aprameya Engineering | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
239 | 16,552 | 926 | 694 | 329 |
Revenue (₹ Cr) |
55 | 2,134 | 342 | 116 | 191 |
Net Profit (₹ Cr) |
5.13 | 309.79 | 55.72 | 12.29 | 11.58 |
Net Margin (%) |
9.22 | 13.89 | 16.04 | 10.59 | 6.03 |
RoE (%) |
7.67 | 9.92 | 25.55 | 11.80 | 10.39 |
Price to Earnings |
46.84 | 51.99 | 16.61 | 56.49 | 32.45 |
Price-To-Book |
3.44 | 5.07 | 1.90 | 4.57 | 3.62 |
Income Statement (₹ Cr)
| Aprameya Engineering | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Operating Revenue
|
55.13 | 1,875.26 | 341.74 | 115.51 | 172.88 |
|
Total Income
|
55.62 | 2,002.19 | 347.44 | 116.04 | 173.93 |
|
Total Expenditure
|
44.60 | 1,436.66 | 243.64 | 93.29 | 147.00 |
|
EBITDA
|
10.54 | 438.59 | 98.10 | 22.22 | 25.88 |
|
Depreciation
|
0.09 | 115.52 | 10.79 | 4.74 | 3.94 |
|
EBIT
|
10.44 | 323.08 | 87.31 | 17.48 | 21.94 |
|
Interest
|
3.64 | 21.42 | 19.47 | 1.35 | 6.55 |
|
Other Income
|
0.49 | 126.93 | 5.70 | 0.54 | 1.05 |
|
Exceptional Items
|
-- | -6.80 | -0.99 | -- | -- |
|
Profit before Tax
|
7.29 | 427.47 | 72.55 | 16.67 | 16.44 |
|
Provision for Tax
|
2.16 | 106.74 | 16.83 | 4.38 | 4.52 |
|
Profit after Tax
|
5.13 | 320.73 | 55.72 | 12.29 | 11.92 |
Liabilities (₹ Cr)
| Aprameya Engineering | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
69.40 | 3,106.17 | 246.19 | 110.33 | 104.19 |
|
Minority Interest
|
0.18 | 43.07 | -- | -- | 9.77 |
|
Non-Current Liabilities
|
1.26 | 120.16 | 101.51 | 16.71 | 7.30 |
|
Current Liabilities
|
10.50 | 666.53 | 209.92 | 29.82 | 91.27 |
|
Total Liabilities
|
82.27 | 3,951.60 | 558.69 | 156.99 | 212.85 |
Assets (₹ Cr)
| Aprameya Engineering | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
8.03 | 1,903.19 | 213.57 | 95.54 | 70.52 |
|
Current Assets
|
73.30 | 2,032.74 | 344.06 | 61.32 | 142.01 |
|
Total Assets
|
82.27 | 3,951.60 | 558.69 | 156.99 | 212.85 |
|
Total Debt*
|
7.14 | 341.62 | 225.48 | 25.45 | 74.48 |
|
Net Current Assets
|
62.80 | 1,366.21 | 134.14 | 31.50 | 50.74 |
|
Contingent Liabilities
|
8.06 | 50.21 | 52.55 | 5.27 | 0.05 |
Cashflow (₹ Cr)
| Aprameya Engineering | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
31.23 | 246.37 | 16.38 | -- | 19.44 |
|
Cash Flow from Investing Activities
|
-4.45 | -225.38 | -29.42 | -- | -20.42 |
|
Cash from Financing Activities
|
-26.66 | 20.15 | 41.64 | -- | 1.11 |
|
Net Cash Inflow / Outflow
|
0.12 | 41.14 | 28.60 | 0.00 | 0.13 |
Ratios
Profitability Ratios
| Aprameya Engineering | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
ROCE (%)
|
12.77 | 14.05 | 22.23 | 14.32 | 13.99 |
|
ROE (%)
|
7.67 | 10.94 | 25.55 | 11.80 | 12.29 |
|
ROA (%)
|
4.56 | 8.89 | 11.01 | 8.54 | 5.92 |
|
EBIT Margin (%)
|
19.99 | 30.16 | 30.37 | 19.70 | 15.58 |
|
Net Margin (%)
|
9.22 | 16.02 | 16.04 | 10.59 | 6.85 |
|
Cash Profit Margin (%)
|
9.46 | 23.12 | 18.40 | 12.56 | 9.17 |
Growth Ratios
| Aprameya Engineering | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-59.37 | 12.30 | 9.13 | 24.96 | 10.81 |
|
EBIT Growth (%)
|
-55.90 | 3.80 | 40.81 | 109.09 | -0.71 |
|
Net Profit Growth (%)
|
-68.18 | -5.27 | 255.32 | 160.94 | -13.01 |
|
EPS Growth (%)
|
-68.34 | -4.88 | 180.69 | 160.94 | -22.66 |
|
Book Value Growth (%)
|
8.00 | 12.14 | 29.61 | 12.53 | 16.14 |
Valuation Ratios
| Aprameya Engineering | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Price / Earnings
|
76.00 | 37.47 | 0.00 | 25.29 | 13.74 |
|
Price / Book Value
|
5.59 | 3.90 | 0.00 | 2.82 | 1.34 |
|
Dividend Yield (%)
|
0.00 | 0.29 | -- | 0.00 | 0.69 |
|
EV/EBITDA
|
35.29 | 21.79 | 1.59 | 14.69 | 7.89 |
|
Market Cap (₹ Cr)
|
387.75 | 12,069.92 | 0.00 | 310.75 | 139.23 |
Solvency Ratios
| Aprameya Engineering | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.10 | 0.11 | 0.92 | 0.23 | 0.71 |
|
Short term debt to equity ratio
|
0.06 | 0.08 | 0.36 | 0.03 | 0.60 |
|
Current Ratio
|
6.98 | 3.05 | 1.64 | 2.06 | 1.56 |
|
Quick Ratio
|
6.73 | 2.40 | 1.19 | 1.34 | 1.05 |
|
Interest Coverage
|
3.00 | 20.96 | 4.73 | 13.37 | 3.51 |
Operating Efficiency Ratios
| Aprameya Engineering | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
100.70 | 28.33 | 36.82 | 22.72 | 38.94 |
|
Asset Turnover
|
0.49 | 0.52 | 0.71 | 0.94 | 0.86 |
|
Receivable days
|
577.64 | 85.20 | 105.22 | 64.80 | 132.22 |
|
Inventory Days
|
32.62 | 69.58 | 93.48 | 56.27 | 89.99 |
|
Payable days
|
666.27 | 77.97 | 146.52 | 52.79 | 69.61 |
|
Cash Conversion Cycle
|
-56.01 | 76.82 | 52.17 | 68.27 | 152.61 |